Dear Ms. Nearing:

Please refer to your Supplemental Biologics License Application (sBLA), dated December 16, 2012, received December 21, 2012, submitted under section 351(a) of the Public Health Service Act for Kepivance® (palifermin).

We acknowledge receipt of your amendment dated May 29, 2013.

This Prior Approval supplemental biologics application provides the final study report for Study 20010133 entitled “A Phase 1 Dose-escalation Study to evaluate the Safety and Pharmacokinetics (PK) of Palifermin in Pediatric Subjects with Acute Leukemias Undergoing Myeloablative Therapy and Allogeneic Hematopoietic Stem Cell Transplant” for BLA 125103/38 PMR-1, listed in the January 5, 2009, post marketing requirement (PMR) letter:

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

We note that your May 29, 2013, submission includes final printed labeling (FPL) for your package insert. We have not reviewed this FPL. You are responsible for assuring that the wording in this printed labeling is identical to that of the approved content of labeling in the structured product labeling (SPL) format.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format, as described at [http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm](http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm), that is identical to the enclosed labeling (text for the package insert) and include the labeling changes
proposed in any pending “Changes Being Effected” (CBE) supplements. Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this BLA, including pending “Changes Being Effected” (CBE) supplements, for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 601.12(f)] in MS Word format that includes the changes approved in this supplemental application.

**REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

We have received your submission dated December 16, 2012, received December 21, 2012, containing the final reports for the following postmarketing requirement listed in the January 5, 2009, post marketing requirement (PMR) letter:

**STN 125103/38 PMR-1**

To conduct a deferred pediatric study under PREA to determine well-tolerated and pharmacologically active doses of palifermin in three patient cohorts defined by age (1-2, 3-11, and 12-16 years) with hematologic malignancies treated with myelotoxic therapy and undergoing hematologic stem cell transplant. In study 20010133, "A Phase 1 Dose-escalation Study to Evaluate the Safety and Pharmacokinetics (PK) of Palifermin in Pediatric Subjects with Acute Leukemias Undergoing Myeloablative Therapy and Allogeneic Hematopoietic Stem Cell Transplant (HSCT)," that will be conducted at approximately seven sites registered with the Pediatric Blood and Marrow Transplant Consortium (PBMTC), 18 to 54 subjects will be treated in the specified age groups. The study will evaluate the safety and pharmacokinetics of palifermin in patients with acute leukemias receiving myelotoxic therapy followed by hematologic stem cell transplant. Three doses (40/mg/kg/day, 60/mg/kg/day, 80/mg/kg/day) will be evaluated in each age cohort in a dose-escalation manner. Age cohorts will be treated simultaneously with the objective to identify a safe, well-tolerated, efficacious dose in each age cohort.

We have reviewed your submission and conclude that the above requirement was fulfilled.
We remind you that there are postmarketing requirements and postmarketing commitments listed in the December 15, 2004 approval letter, the January 5, 2009 postapproval postmarketing requirement letter, the January 16, 2009 postapproval postmarketing commitment letter, and the May 10, 2011 postapproval postmarketing commitment letter that are still open.

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved BLA (in 21 CFR 600.80 and in 21 CFR 600.81) and Postmarketing Study Commitments subject to reporting requirements of 21 CFR 601.70.

If you have any questions, call CAPT Diane Hanner, Regulatory Project Manager, at (301) 796-4058.

Sincerely,

{See appended electronic signature page}

Robert C. Kane, M.D.
Deputy Director for Safety,
Division of Hematology Products
Office of Hematology and Oncology Products
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ROBERT C KANE
05/30/2013